	Application No.	Applicant(s)
	10/799,415	BAKKER-ARKEMA ET AL.
Notice of Allowability	Examiner	Art Unit
	Raymond J. Henley III	1614
The MAILING DATE of this communication appeal of the communication appeal claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT ROOT the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apply or other appropriate communication (IGHTS. This application is subject to and MPEP 1308.	plication. If not included not will be mailed in due course. THIS
1. This communication is responsive to the amendment filed	March 14, 2005.	
2. \boxtimes The allowed claim(s) is/are <u>6,8,11 and 14</u> .		
3. \boxtimes The drawings filed on <u>March 12, 2004</u> are accepted by the	e Examiner.	
4. ☐ Acknowledgment is made of a claim for foreign priority una) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	e been received. e been received in Application No ocuments have been received in this of this communication to file a reply	national stage application from the
 5. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which giv 6. CORRECTED DRAWINGS (as "replacement sheets") must 	es reason(s) why the oath or declara	'S AMENDMENT or NOTICE OF ation is deficient.
(a) ☐ including changes required by the Notice of Draftspers 1) ☐ hereto or 2) ☐ to Paper No./Mail Date (b) ☐ including changes required by the attached Examiner Paper No./Mail Date Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the second sheet.	son's Patent Drawing Review (PTO 's Amendment / Comment or in the C	Office action of . ngs In the front (not the back) of
 DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT 	osit of BIOLOGICAL MATERIAL r FOR THE DEPOSIT OF BIOLOGIC	must be submitted. Note the AL MATERIAL.
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview Summary Paper No./Mail Dat 08), 7. ⊠ Examiner's Amendr	te <u>03242005</u> .
	RJ Pi	NYMOND HENLEY-III RIMARY EXAMINER AU 1614

ill

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04) Application/Control Number: 10/799,415

Art Unit: 1614

EXAMINER'S COMMENT/AMENDMENT

Comment

Applicants' amendment filed March 14, 2005 has been received and entered into the application. Accordingly, claims 3-5, 7, 9, 10, 12, 13 and 15 have been canceled and claims 6, 8, 11 and 14 have been amended.

Because the claims as amended are limited to a combination of compounds for which unexpected results have been demonstrated, (see the previous Office action dated January 19, 2005, especially page 3 at the third paragraph), the claim rejection under 35 U.S.C. § 103, as set forth in the previous Office action, has been overcome and is therefore withdrawn.

Amendment

An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Andrew J. Leon on March 24, 2005.

The amendment to claim 8 was suggested by the Examiner because the expression "heart failure and other edematous conditions" appears unduly limiting. It is clear from the present specification that Applicants' invention does not require that both heart failure and other edematous conditions to be treated at the same time, e.g., see the present specification at page 6, lines 14-17 and 25 where the treatment of congestive heart failure and other edematous conditions are set forth as separate therapeutic objectives.

Page 3

Application/Control Number: 10/799,415

Art Unit: 1614

The application has been amended as follows:

In the Drawings:

The bottom of the second sheet of drawings is partially obscured and it should read as --Figure 2---

In the Claims:

In claim 8, line 2, the expression "congestive heart failure and other edematous conditions" has been changed to ---congestive heart failure or other edematous conditions---; and line 3, ---to the mammal--- has been inserted after "administering".

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Raymond J. Henley III whose telephone number is 571-272-0575. The examiner can normally be reached on M-F, 8:30 am to 4:00 pm Eastern Time.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (tol)-free).

Raymond J Henley III Primary Examiner Art Unit 1614